New treatment for lung cancer metastases using a special therapy
Official title: Development of IFNA2-LNP01 for tumor lung metastases immunotherapy
Funded at Chemedimmune, INC. · NIH-10820250 · Data updated 2026-11-12
This study is testing a new treatment called IFNA2-LNP01 to help cancer patients with lung metastases by using a special delivery system to boost their immune system before surgery, with the hope of shrinking tumors and making surgery safer and more effective.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chemedimmune, INC. NIH-funded |
| Lab location | 1 site (Martinez, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $320,597 |
| NIH project number | 1R43CA287611-01 |
| Project ID | NIH-10820250 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with lung metastases from colorectal cancer or other malignancies who are currently not eligible for surgery.
✕Less likely to help
Patients with lung metastases that are not amenable to surgical intervention or those with other advanced-stage cancers may not benefit from this research.
What this research studies
This research focuses on developing a new therapy called IFNA2-LNP01, which is designed to treat lung metastases in cancer patients. The therapy involves using a lipid nanoparticle to deliver a specific type of DNA that activates the immune system to fight cancer cells in the lungs. By administering this treatment before surgery, the goal is to reduce the size or number of lung metastases, making more patients eligible for potentially life-saving surgical procedures. The research aims to improve survival rates for patients with colorectal cancer and other cancers that have spread to the lungs.
Why it matters
Potential benefit: If successful, this research could significantly increase the number of patients eligible for surgical treatment of lung metastases, potentially improving survival rates.
How similar studies have gone: While the approach of using immune therapies for cancer treatment is gaining traction, this specific application of IFNA2-LNP01 for lung metastases is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Chemedimmune, INC.
Martinez, United States Active
Researchers
- Principal investigator: Redd, Priscilla Simon — Chemedimmune, INC.
- Study coordinator: Redd, Priscilla Simon
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.